NVT ALLEGRA TAVI System TF in Failing Surgical Aortic Bioprosthesis

NCT ID: NCT03287856

Last Updated: 2020-01-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-11
• Study Completion Date: 2019-10-27

Brief Summary

The study investigates the technical feasibility of the replacement of failed surgical bioprosthetic aortic valves by the ALLEGRA Transcatheter Heart Valve (THV) and describes the safety and performance profile

Conditions

Transcatheter Aortic Valve Implantation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment

Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis

Group Type: EXPERIMENTAL

Transcatheter Aortic Valve Implantation (TAVI)

Intervention Type: DEVICE

Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis

Interventions

Transcatheter Aortic Valve Implantation (TAVI)

Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• ≥18 years
• Symptomatic degeneration of aortic bioprosthesis showing echocardiographically mean aortic gradient >40mmHg or peak jet velocity >4.0m/s and AVA<1.0cm2 OR symptomatic patients with severe bioprosthetic valve insufficiency.
• High risk for redo surgery defined by STS ≥10% / EuroScore II ≥7% OR as assessed by the heart team
• Has signed the Patient Informed Consent Form
• Willing and able to comply with requirements of the study, including all follow-up visits
• Female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation

Exclusion Criteria

• Low position of the coronary ostia, especially in combination with shallow sinuses
• Echocardiographic evidence of intracardiac mass, thrombus or vegetation
• Significant aortic disease such as severe obstructive calcification or marked tortuosity or kinking which will preclude a safe advancement of the ALLEGRA TAVI System TF
• Iliofemoral vessel conditions such as severe obstructive calcification, severe tortuosity or kinking that would preclude safe placement of an 18 Fr introducer sheath or make endovascular access to the aortic valve impossible
• Severe mitral insufficiency
• Internal diameter of the bioprosthesis is ≤16 mm or >28 mm
• Patient prosthesis mismatch (EOAi ≤0.65 cm2/m2) as the underlying cause of the poor valve function and need for re-intervention
• Non-valvular stenosis as the underlying cause of the poor valve function and need for re-intervention
• Failing pre-existing prosthetic heart valve or prosthetic ring in any other position than aortic
• Partially detached leaflets that in the aortic position may obstruct a coronary ostium.
• Existence of aortic conduit, aortic arch replacement, stentless bioprosthesis and autologous valve replacement
• Paravalvular leak of the failing surgical bioprosthesis (between failing surgical bioprosthesis and native annulus)
• LVEF <20%
• Evidence of active endocarditis or other acute infections
• End stage renal disease requiring chronic dialysis or creatinine clearance <20 ml/min or serum creatinine >3.0 mg/dl (264 µmol/l)
• Known hypersensitivity to contrast media, which cannot be adequately pre-medicated or contraindication to anticoagulant or anti-platelet medication or to Nitinol alloy or to bovine tissue
• Evidence of an acute myocardial infarction within the past 30 days
• Cerebral vascular accident (TIA, Stroke) within past 6 months (≤180 days)
• Evidence of active peptic ulcer or upper gastrointestinal bleeding within past 90 days
• Untreated clinically significant coronary artery disease requiring revascularization
• Hemodynamic instability (e.g. cardiogenic shock) requiring inotropic support or mechanical heart assistance (e.g. VAD, IABP)
• Uncontrolled (therapy resistant) atrial fibrillation
• Need for emergency surgery for any reason
• Life expectancy ≤ 12 months due to other medical illness
• Currently participating in another investigational drug or device study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NVT GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ulrich Schaefer, MD

Role: PRINCIPAL_INVESTIGATOR

Universitäres Herzzentrum Hamburg, Germany

Locations

Segeberger Kliniken, Herzzentrum

Bad Segeberg, , Germany

Immanuel Klinik Bernau Herzzentrum Brandenburg

Bernau bei Berlin, , Germany

Mitteldeutsches Herzzentrum Universitätsklinikum Halle (Saale)

Halle, , Germany

Asklepios Klinik St. Georg

Hamburg, , Germany

Universitäres Herzzentrum Hamburg GmbH

Hamburg, , Germany

Countries

Germany

References

Schafer U, Butter C, Landt M, Frerker C, Treede H, Schirmer J, Koban C, Allali A, Schmidt T, Charitos E, Conradi L. Thirty-day outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL multicentre, single-arm, pilot study. EuroIntervention. 2019 Oct 4;15(9):e757-e763. doi: 10.4244/EIJ-D-19-00331.

Reference Type: RESULT

PMID: 31355750 (View on PubMed)

Related Links

https://eurointervention.pcronline.com/article/thirty-day-outcomes-of-a-novel-transcatheter-heart-valve-to-treat-degenerated-surgical-valves-the-vivall-multi-center-single-arm-pilot-study

Related Info

Other Identifiers

NVT03VIV

Identifier Type: -

Identifier Source: org_study_id